Chemomab Therapeutics (CMMB)
(Delayed Data from NSDQ)
$1.76 USD
-0.03 (-1.68%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $1.75 -0.01 (-0.57%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CMMB 1.76 -0.03(-1.68%)
Will CMMB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CMMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMMB
Chemomab Therapeutics (CMMB) Upgraded to Buy: Here's What You Should Know
Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?
CMMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Is a Great 'Buy the Bottom' Stock Now
Chemomab (CMMB) Up on Fast Track Designation to CM-101 for PSC
Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
Other News for CMMB
Chemomab Therapeutics to Present at September 2024 Investor Conferences
CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Chemomab Therapeutics GAAP EPS of -$0.01
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update